Cancer Surgery

  • Radio Frequency Ablation (RFA) of Liver Tumors

    Radio Frequency Ablation (RFA) of liver tumors offers our patients a valuable treatment option for non-operable metastatic liver tumors.  RFA is a medical technology that destroys liver tumors when surgical removal is not an option.  This can be done in combination with removing some tumors and ablating (destroying) others.  Occasionally for solitary lesions it can even be done through the skin (percutaneously) using CT guidance.

    Learn more at RITA
  • Minimally Invasive Radio-guided Parathyroidectomy (MIRP)
    The MIRP procedure has no become the preferred method of removing parathyroid tumors.  MIRP has a higher success rate and lower complication rate than standard parathyroid surgery.  This minimal parathyroid surgical technique has gained wide acceptance as the most advanced, least invasive, and preferred method for operating on parathyroids.  The outpatient procedure generally takes 30 minutes or less.
  • Pancreatic Cancer

    Pancreatic cancer is the second most common gastrointestinal malignancy, but it has the worst prognosis, with less than 20% of patients surviving one year after diagnosis and less than 5% surviving five years.  The only potentially curative treatment is operative resection (Whipple procedure).  Dr. Beitsch performs between 6-10 whipple procedures yearly at Medical City Dallas Hospital with no perioperative deaths in the last ten years.

    Learn more at www.pancan.org
  • Stomach Cancer

    Gastric cancer is the fourth most frequent gastrointestinal cancer in the U.S., with an associated 5-year relative survival rate of 59%.  Surgical resection is necessary to cure local or regional disease, but recently postoperative combined chemotherapy and radiotherapy have shown to improve survival rates.  Patients with gastric cancer typically present with upper gastrointestinal complaints such as pain, heartburn, dysphagia, and bloating.  Unfortunately, by the time these symptoms are evaluated about one third of gastric cancer patients already have spread beyond the stomach.  In the vast majority of cases, diagnosis is made by flexible esophagogastroduodenoscopy (EGD) with biopsy.  Dr. Beitsch has had a long interest in gastro-intestinal stromal tumors (GIST) and has participated in the early studies of the very effective oral drug, Gleevec, which is used in treating GIST.

    Learn more at www.liferaft.org